New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free
Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, November 12, 2026

Back to the front page

Looking Back at Another Successful Thesis

DoubleU Games raised its all-cash tender offer for DoubleDown Interactive minority holders to $16.25 per ADS from $11.25 after net cash made the earlier bid untenable.

DDI $781M
The Value Road 4 clicks

From X

@RagingVentures

Raging Capital Ventures on X

The capex spend is mind boggling, but I held my nose and bought $META today around $590-600 I don’t how the AI bet will shake out, but I do know that… - $META Reels is sucking up engagement share from everyone, even $NFLX - $GOOG search refers are in free fall, which should benefit $META’s ad network - Zuck is the best owner-operator in the business who is willing to pivot if necessary - There are tremendous AI cost efficiency opps in core $META operations (Note: I have a long and fruitful history with $META and my family members still own their shares going back to 2013, knock on wood)
@RagingVentures

Raging Capital Ventures on X

I’m now very bullish on $CMCSA as well. In my view, Peacock/NBCU/theme parks are likely worth around the current market cap alone. Importantly, Peacock / NBC are now competitively advantaged in sports media thanks to a superior combination of reach with their NBC broadcast network and their scaled streaming platform. Comcast Cable is struggling, but they have frontloaded a lot of pain; wireless and the bundle is a growth engine; and the balance sheet is actually a strength (not a weakness). Plus, the 6% dividend pays you to wait for the spin in 2027.
@RagingVentures

Raging Capital Ventures on X

Not the greatest quarter but no change in my $CHTR view, although I did sell some of my October calls today. Owning common and LEAPs are most interesting now. The Cox acquisition should close in mid- to late-August, which I view as a catalyst for analysts and investors to revisit their models. $CHTR is now trading at around 2x pro forma 2028 FCF per share, with incredible balance sheet optionality (which they have started to monetize via buybacks and swaps at a discount). I also think $CHTR has front-loaded a lot of ARPU pain and invested heavily to stabilize video in recent years. While broadband will remain challenged, I don’t believe the worst case scenarios and think wireless growth and pricing can provide a valuable offset.
@david_katunaric 1 click

Mikro Kap David on X

Yesterday I dug deeper into an 🇦🇺 special situation that reminds me of when I first found $ICCC back in September 2025. In both cases, a high-quality core business is taking share in an oligopolistic niche with a superior product, yet its underlying economics are obscured by a legacy development program that has consumed decades of spending and exhausted nearly everyone who has ever owned the stock. As was the case with ImmuCell, I don’t think this setup requires regulatory approval to work. FAA approval would create significant upside, while abandonment would remove the cost burden, allowing management to focus entirely on the core business and letting its underlying economics shine through. There is also a less “dramatic” but plausible third path: the legacy program’s drag on profitability continues to diminish while the attractive aerospace business grows around it. Both situations also brought experienced industry executives into senior leadership at a potentially important turning point. And, so far, I believe the new management team is making the right moves. There are several ways this could play out, but I believe the favorable outcomes are more likely, while the unfavorable ones shouldn’t carry much downside at the current valuation. I wrote up this company now so that, as new information emerges, you’ll know what matters, what doesn’t, and how each development changes the risk-reward. That should put you in a position to act while others are still parsing headlines and catching up. Link in the comment below.

Investor Letters

All letters

Qure Anniversary Update

UniQure’s Huntington’s disease BLA has a May 1, 2027 priority-review date, with an FDA advisory committee expected in late first quarter.

QURE $1.7B
Triple S Special Situations Investing 2 clicks

Big Short: Fidelity & Guaranty

F&G’s main insurer held $66.5 billion of assets against $1.38 billion of statutory capital, while private credit, reinsurance dependence…

FG $3B
Mispriced Assets 5 clicks

Top Rebound Stocks for Nov’26

Texas Pacific Land's 50% selloff reflects faded data-center expectations, while its Permian royalty business generated $498 million of 2025…

TPL $20B
Rebound Capital 5 clicks

Peloton: Beyond The Bike

Peloton’s connected-fitness subscribers fell 9% year over year to 2.475 million, with another high-single-digit holiday decline forecast as…

PTON $2.5B
TSOH Investment Research 4 clicks
MONOY · long

Monotaro CO LTD

MonotaRO, traded as MONOY in the U.S. and 3064 in Japan, is a Japanese MRO distributor recommended as a long.

MONOY $7.3B
Value Investors Club 1 click

DoorDash’s FBA Moment

DoorDash’s $17 billion Instacart deal targets DashMart warehouse scale, where 99%+ order accuracy and faster delivery address the limits of…

DASH $75BKR $42B
MBI Deep Dives 3 clicks

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

YouTube 4

Blogs 15

Seeking Alpha 87 of 294

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.